BioSight
Companies

RDUS

NASDAQBOSTON, MA
Radius Health

Radius Health is a biopharmaceutical company focused on bone health, neuroscience, and oncology with TYMLOS (abaloparatide), a small molecule approved in 2017 for postmenopausal osteoporosis, generating commercial revenue across U.S. markets. The company has late-stage candidates including abaloparatide-SC for male osteoporosis (Phase 3 completed, NDA filing planned), elacestrant, a selective estrogen receptor degrader for ER+/HER2- advanced breast cancer licensed to Berlin-Chemie (Phase 3 completed), and RAD011, a synthetic cannabidiol oral solution in Phase 2/3 development for Prader-Willi Syndrome.

$30.00+0.00%1Y
RDUS · daily close · illustrative · 0 catalysts marked
$30$30$30$30$30Feb '26Mar '26Apr '26Apr '26
1Y high$30.001Y low$30.00range$0.00(0%)past catalysts

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar